# Trade Mark Journal No.2026/015 10 April 2026

## WO0000001895694 (5,42)

Office of origin: United States of America

Date of International Registration:3 December 2025
Date of designation in the UK: 3 December 2025

International priority date claimed: 4 June 2025 (United States of America) (99218525)

Class 5
  Antibodies for medical purposes; diagnostic biomarker reagents for medical purposes; protein arrays for medical diagnosis purposes; diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic preparations for medical purposes; pharmaceutical preparations for the treatment of cancer, oncologic diseases and disorders, inflammation and immunity diseases and disorders, immunodeficiency diseases and disorders, genetic diseases and disorders, metabolic diseases and disorders, neurodegenerative diseases and disorders, kidney diseases and disorders, eye diseases and disorders, uveitis, glomerulosclerosis, glomerulonephritis, cardiovascular diseases and disorders.
Class 42
  Pharmaceutical research and development; research and development services in the field of antibodies; providing medical and scientific research information; consulting services in the field of pharmaceutical research and development; consulting services in the field of biotechnology; consulting services in the field of pharmacogenetics; research and development in the field of biologics, namely, antibodies and peptides for the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; research and development in the field of pharmaceuticals, biopharmaceuticals, and biotechnologies for the treatment of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; research and development in the field of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics in the field of cancer, immunology and inflammation diseases, autoimmune diseases, autoimmune disorders, genetic disorders, metabolic diseases, neurodegenerative diseases, kidney diseases, eye diseases, uveitis, glomerulosclerosis, glomerulonephritis, and cardiovascular diseases; research and development in the field of proteomics, transcriptomics, and bioinformatics.

Bluefin Biomedicine, Inc.

Representative: Keith Toms, Esq. McCarter & English, LLP, 265 Franklin Street, Boston MA 02110, UNITED STATES OF AMERICA